Pharmacology and Toxicology

Faculty: Malcolm J. Moore, MD

Malcolm J. Moore, MDMalcolm J. Moore, MD
Professor of Medicine and Pharmacology
Head, Div. of Medical Oncology and Hematology, Department of Medicine 
Princess Margaret Hospital, UHN, Mount Sinai Hospital

General Research Areas: Clinical Pharmacology; Development of Novel Anti-cancer Therapies

Not taking new graduate students

Dr. Moore's laboratory and clinical research studies focus on the development and testing of new cancer therapies. He directs the drug development program at OCI/PMH which involves the evaluation and early clinical testing of novel agents for cancer therapy. Laboratory activities include the development and use of pharmacokinetic and pharmacodynamic assays for use in phase I and II studies of new drugs using techniques such as HPLC, PCR, western blotting and gene arrays. In the past few years agents evaluated have included standard cytotoxic agents as well as newer targeted therapies. 

The clinical activities of the drug development program include the largest phase I program in Canada with studies supported by agencies such as NCI-US, NCIC and the pharmaceutical industry, and an NIH grant to support phase II drug development of novel anti-cancer agents. Agents under study include anti-sense compounds, anti-vascular agents, EGFR and other signal transduction inhibitors and cell cycle modulators. 

Selected Publications

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-65.

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N. Engl J Med. 2007; 357:2040-8.

Moore MJ, David Goldstein, John Hamm, Arie Figer, Joel R Hecht, Steven Gallinger, Heather J Au, Pawel Murawa, David Walde, Robert Wolff, Daniel Campos, Robert Lim, Keyue Ding, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar. Erlotinib plus Gemcitabine Compared With Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National ancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960-1966.

Ribic C, Sargent D, Moore MJ, Thibodeau S, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite instability as a predictor of survival benefit from 5-FU based adjuvant chemotherapy in colon cancer. N Engl J Med. 2003; 349:247-57.

Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Tu D, Zee B, Humphrey R, Seymour L. A Comparison of Gemcitabine versus the Matrix Metalloproteinase Inhibitor BAY 12-9566, in Patients with Advanced or Metastatic Adenocarcinoma of the Pancreas. A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21:3296-302.


Division of Medical Oncology & Hematology 
Ontario Cancer Institute/Princess Margaret Hospital 
University Health Network
Room 5-708 
610 University Avenue 
Toronto, Ontario 
M5G 2M9 
Phone: [416]946-2263 
FAX: [416]946-2082